Sana Biotechnology has closed its first round at more than $700m after investors including GV swung behind its vision to commercialise cell therapies.

US-based stem cell medicine developer Sana Biotechnology closed its inaugural funding round on Tuesday, having raised more than $700m from investors including GV, a corporate venturing subsidiary of internet technology group Alphabet. The round also featured F-Prime Capital, a fund owned by investment and financial services group Fidelity, as well as Canada Pension Plan Investment…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.